enzyme. The Km (11jpM) of the reaction is one-third of that for the conversion of angiotensin I into angiotensin II. As suggested by the Km values, bradykinin, peptide BPP9a and angiotensins II and III are better inhibitors of the formation of angiotensin II than of the formation of angiotensin III.
A number of investigators have postulated that angiotensin III (des-Asp1-angiotensin II) may be a primary secretogogue of aldosterone Campbell et al., 1974; Spielman et al., 1975) . Although angiotensin III is less active than angiotensin II on vascular smooth muscle, it has a faster onset of action and is slightly more potent than angiotensin II in stimulating the release of aldosterone from dispersed cells of the adrenal cortex (Chiu & Peach, 1973) . Angiotensin III also differs from angiotensin II in terms of its response to antagonists. For example, (Sar',Ala8]-angiotensin II is a good antagonist of the effects of angiotensin II on the adrenal cortex but is a poor antagonist of angiotensin III (Bravo et al., 1975 Nagatsu et al., 1970; Ryan, 1974) ; however, the enzymes have not been purified to homogeneity, and little is known of their specificity or selectivity of action.
In early studies on the immediate metabolic fate of [[14C] Leu10]angiotensin I during passage through the lungs, a radioactive product was found that possessed properties like those expected of des-Aspl-angiotensin I (Ryan et al., 1970) . On molecular-sieve chromatography, the product was Vol. 155 eluted like angiotensin I, but migrated on electrophoresis like a compound having a net positive charge greater than that of angiotensin I. In view of the position of the radioactivity within the parent compound and of the distribution of charged residues in angiotensin I (H-Asp-Arg-Val-Tyr-IleHis-Pro-Phe-His-Leu-OH), it seems likely that the product was des-Asp1-angiotensin I.
Considering the abundance ofangiotensin-converting enzyme in plasma, lung and other tissues and the accessibility of the lung enzymes to circulating substrates (Skeggs et al., 1956; Roth et al., 1969; Ryan et al., 1972 Ryan et al., , 1975 , we have begun to examine the possibility that angiotensin III may be formed from des-Asp'-angiotensin I. Angiotensin-coverting enzyme acts as a dipeptidyl carboxypeptidase, but its selectivity of action appears to depend in part on N-terminal residues distant from the site of hydrolysis (Dorer et al., 1974a . None of the N-terminal higher homologues of the nonapeptide bradykinin (e.g. Lys-bradykinin or Met-Lys-bradykinin) is hydrolysed as rapidly as is bradykinin itself. Similarly, the tetradecapeptide renin substrate is hydrolysed at less than one-tenth the rate observed for hydrolysis of its C-terminal nonapeptide . In the present study we have found that des-Aspl-angiotensin I is a better substrate for angiotensin-converting enzyme than is angiotensin I.
Materials and Methods
All of the following experiments used pig lung angiotensin-converting enzyme (fraction G as described by Dorer et al., 1972 Tominaga et al., 1975) , angiotensin II, des-Aspl-angiotensin I and lower homologues (angiotensin I4(3-10)-octapeptide,
-(4-10)-heptapeptide and -(5-10)-hexapeptide; structures shown in Table 1 ) were synthesized by the solid-phase technique (Stewart & Young, 1969) . The polypeptides were purified by chromatography on Sephadex G-25 and/or by countercurrent distribution.
Rates of hydrolysis of angiotensin I or des-Asplangiotensin I by pig lung angiotensin-converting enzymewere measured in terms oftheformation ofthe dipeptide His-Leu by the automated fluorescence technique described by Boucher et al. (1972) . The dipeptide His-Leu forms a fluorophor on reaction with o-phthaldialdehyde. Under the conditions of the assay, the products of reaction of o-phthaldialdehyde with free histidine and leucine do not interfere. Except for studies for estimating Km and Vmax., each substrate was used in a final concentration of 25 or 50gM. Incubations were carried out at 37°C in 50m-sodium phosphate buffer, pH7.5. Except where indicated, the incubation mixtures contained 100mM-NaCl. Reactions were begun by adding angiotensin-converting enzyme at a final concentration of 0.286ng of protein/mi.
Corrected for purity (approx. 35 %) and assuming a molecular weight of 129000 (Das & Soffer, 1975) , the enzyme was at a final concentration of 770pM. After it was established that the reactionsproceeded lineaxly over a period of 60min, all subsequent incubations were for 60min. Reactions were terminated by heating the mixtures in a boiling-water bath for 5min. In studies on the effects of inhibitors, the enzyme was preincubated at 37°C with a given inhibitor for 2min.
Results and Discussion
At pH7.5, in the presence of lOOmM-NaCI, the K,,, for the hydrolysis of des-Aspl-angiotensin I is onethird of that for angiotensin I (Table 1) . However, the Km values for lower C-terminal homologues are greatly elevated, a finding that suggests that, if these lowerhomologues are formed in vivo, they are unlikely to interfere with the action of converting enzyme on angiotensin I. Values for Km and Vmax. were estimated from Lineweaver-Burk plots, and it can be argued that the threefold difference between the Km of des-Aspl-angiotensin I and that of angiotensin I may be near to experimental error. Since the hydrolysis of both substrates was measured in terms of the formation of His-Leu, we were unable to determine whether des-Aspl-angiotensin I inhibits the hydrolysis of angiotensin I. Possibly the question can be resolved definitively by using tracer amounts of
In view of the different pharmacological effects of angiotensin II and III, whether converting enzyme has a greater affinity for des-Aspl-angiotensin I than for angiotensin I could well be a question of physiological significance. Should des-Aspl-angiotensin I and angiotensin I occur in equimolar quantities, the formation of an aldosterone secretogogue would be favoured over the formation of a pressor agent (cf. Bravo et al., 1975) . A higher affinity of the enzyme for des-Aspl-angiotensin I is favoured by data shown in Table 2 . Angiotensins II and ITI, bradykinin and peptide BPP9a are better inbibitors of the hydrolysis of angiotensin I than of the hydrolysis of des-Aspl-angiotensin I.
The influence of chloride concentration on the hydrolysis of des-Aspl-angiotensin I by converting enzyme differed from that found when angiotensin I was used as substrate. Hydrolysis of des-Aspl-angiotensin I proceeded at its maximum rate (783nmol/ min per mg of enzyme protein) when chloride was in a final concentration of 10mm, the optimal chloride concentration for hydrolysis of bradykinin (Dorer et al., 1974b) . The rate was decreased by 33% when chloride was at 1 or 50mM and by 51 % when chloride was at 100mM, the optimal chloride concentration for hydrolysis of angiotensin I (Dorer et al., 1972) . Like bradykinin, des-Asplangiotensin I is hydrolysed in the absence of chloride (25% of its maximum rate). Under these conditions hydrolysis of angiotensin I is almost negligible (approx. 5 % of its maximum rate).
Results of the present study raise several points of possible importance. If des-Aspl-angiotensin I occurs in vivo, it can be converted readily into angiotensin III. Judged by the relatively low Km of the reaction ofdes-Aspl-angiotensin I with converting enzyme, the formation of angiotensin III might be favoured over the formation ofangiotensin II. In view of the potency of angiotensin III as an aldosterone secretogogue, it may be of interest that the formation of angiotensin III is accelerated when chloride concentrations fall below the physiological range (approx. 100mM). Dorer et al. (1972) have shown that the effects of chloride on the conversion of angiotensin I into angiotensin II are biphasic, with the highest rate occurring at 100mM-chloride. The possibility is suggested that the formation of angiotensin II is suppressed when chloride concentrations fall on either side of the physiological range.
An unexpected finding was that [Sar',Ala']angiotensin II, an antagonist of pharmacological effects of angiotensin II (Pals et al., 1971) , is a good inhibitor of the conversion of angiotensin I into angiotensin II. As shown in Table 2 , when [Sar',Ala8]angiotensin II and angiotensin I are used in equimolar quantities the rate of formation of angiotensin II is halved.
However, as used clinically, [Sari, Ala8] angiotensin II has been reported to reach concentrations in venous blood of up to 1 ug/ml (Pettinger et al., 1975) . Thus, in vivo, the molar concentration of [Sar',Ala8]-angiotensin II may exceed that of angiotensin I by more than 10000-fold. Under these conditions it is possible that conversion of angiotensin I into angiotensin II does not occur. It must be emphasized, however, that the present studies examined reactions of angiotensin-converting enzyme in a simple system in vitro, and the results may not be applicable in full to reactions occurring in vivo.
